, Volume 190, Issue 3, pp 327–332 | Cite as

Adipokines and Systemic Inflammation in Weight-Losing Lung Cancer Patients

  • Sule T. Gulen
  • Fisun KaradagEmail author
  • Aslihan B. Karul
  • Naciye Kilicarslan
  • Emel Ceylan
  • Nilgun K. Kuman
  • Orhan Cildag



Cancer cachexia is a devastating condition leading to loss of function and independence, decreased performance status, decreased quality of life, and poor prognosis. Adipokines play a role in a wide variety of physiological or pathological processes, including immunity and inflammation, in addition to having significant effects on metabolism and lipogenesis. The objective of the present study was to investigate the relationship of adipokines and systemic inflammation in weight-losing advanced-stage non-small-cell lung cancer (NSCLC) patients.


Sixty-three male NSCLC patients (stages III and IV) and 25 age- and sex-matched controls were included. NSCLC patients were further divided into subgroups as those with a > 5% weight loss in last 6 months and those who did not. Serum leptin, adiponectin, and TNF-α concentrations were measured by ELISA using commercially available kits.


The positive acute-phase reactants (APR) CRP, leukocyte, ferritin, thrombocyte, and fibrinogen were higher in the NSCLC group. Serum albumin level (which is a negative APR) was lower in the cancer group, whereas there was no difference in transferrin level between the groups. TNF-α and leptin concentrations were similar in the cancer group and the control group, whereas adiponectin was lower in the cancer group. There was a difference in thrombocyte and transferrin levels between patients with and without weight loss, whereas CRP, TNF-α, and adiponectin levels were similar. Leptin was lower in weight-losing cancer patients. However, there was no correlation between adipokines and markers of systemic inflammation.


These results revealed a lack of association between adipokine levels and systemic inflammation with cancer cachexia.


Adipokines Lung cancer Systemic inflammation Weight loss 



The study was funded by the Adnan Menderes University Research Foundation.

Conflict of interest



  1. 1.
    Deans C, Wigmore SJ (2005) Systemic inflammation, cachexia and prognosis in patients with cancer. Curr Opin Clin Nutr Metab Care 8:265–269PubMedCrossRefGoogle Scholar
  2. 2.
    Scott HR, McMillan DC, Brown DJF, Forrest LM, McArdle CS, Milroy R (2003) A prospective study of the impact of weight loss and the systemic inflammatory response on quality of life in patients with inoperable non-small cell lung cancer. Lung Cancer 40:295–299PubMedCrossRefGoogle Scholar
  3. 3.
    McKeown DJ, Brown DJF, Kelly A, Wallace AM, McMillan DC (2004) The relationship between circulating concentrations of C-reactive protein, inflammatory cytokines and cytokine receptors in patients with non-small-cell lung cancer. Br J Cancer 91:1993–1995PubMedCrossRefGoogle Scholar
  4. 4.
    Lago F, Dieguez C, Gómez-Reino J, Gualillo O (2007) Adipokines as emerging mediators of immune response and inflammation. Nat Clin Pract Rheumatol 3:716–724PubMedCrossRefGoogle Scholar
  5. 5.
    Trayhurn P, Wood IS (2004) Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 92:347–355PubMedCrossRefGoogle Scholar
  6. 6.
    Malli F, Papaioannou AI, Gourgoulianis KI, Daniil Z (2010) The role of leptin in the respiratory system: an overview. Respir Res 11:152–168PubMedCrossRefGoogle Scholar
  7. 7.
    Otero M, Lago R, Lago F, Casanueva FF, Dieguez C, Gómez-Reino JJ, Gualillo O (2005) Leptin, from fat to inflammation: old questions and new insights. FEBS Lett 579:295–301PubMedCrossRefGoogle Scholar
  8. 8.
    Popa C, Netea MG, Radstake TR, van Riel PL, Barrera P, van der Meer JW (2005) Markers of inflammation are negatively correlated with serum leptin in rheumatoid arthritis. Ann Rheum Dis 64:1195–1198PubMedCrossRefGoogle Scholar
  9. 9.
    Bruun JM, Lihn AS, Verdich C, Pedersen SB, Toubro S, Astrup A, Richelsen B (2003) Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab 285:527–533Google Scholar
  10. 10.
    Detterbeck FC, Boffa DJ, Tanoue LT (2009) The new lung cancer staging system. Chest 136:260–271PubMedCrossRefGoogle Scholar
  11. 11.
    Martin F, Santolaria F, Batista N, Milena A, Reimers EG, Brito MJ, Oramas J (1999) Cytokine concentrations (IL6 and IFNγ) acute phase response and nutritional status as prognostic factors in lung cancer. Cytokine 11:80–86PubMedCrossRefGoogle Scholar
  12. 12.
    Inui A (2002) Cancer anorexia-cachexia syndrome: current issues in research and management. CA Cancer J Clin 52:72–91PubMedCrossRefGoogle Scholar
  13. 13.
    Simons JP, Schols AM, Buurman WA, Wouters EF (1999) Weight loss and low body cell mass in males with lung cancer: relationship with systemic inflammation, acute-phase response, resting energy expenditure, and catabolic and anabolic hormones. Clin Sci 97:215–223PubMedCrossRefGoogle Scholar
  14. 14.
    Carlson GL, Saeed M, Little RA, Irving MH (1999) Serum leptin concentrations and their relation to metabolic abnormalities in human sepsis. Am J Physiol 276:658–662Google Scholar
  15. 15.
    Schols AM, Creutzberg EC, Buurman WA, Campfield LA, Saris WH, Wouters EF (1999) Plasma leptin is related to proinflammatory status and dietary intake in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 160:1220–1226PubMedGoogle Scholar
  16. 16.
    Murdoch DR, Rooney E, Dargie HJ, Shapiro D, Morton JJ, McMurray JJ (1999) Inappropriately low plasma leptin concentration in the cachexia associated with chronic heart failure. Heart 82:352–356PubMedGoogle Scholar
  17. 17.
    Mantovani G, Maccio A, Madeddu C, Mura L, Massa E, Mudu MC, Mulas C, Lusso MR, Gramignano G, Piras MB (2001) Serum values of proinflammatory cytokines are inversely correlated with serum leptin concentrations in patients with advanced stage cancer at different sites. J Mol Med 79:406–414PubMedCrossRefGoogle Scholar
  18. 18.
    Alemán MR, Santolaria F, Batista N, de La Vega M, González-Reimers E, Milena A, Llanos M, Gómez-Sirvent JL (2002) Leptin role in advanced lung cancer. A mediator of the acute phase response or a marker of the status of nutrition? Cytokine 19:21–26PubMedCrossRefGoogle Scholar
  19. 19.
    Simons JP, Schols AM, Campfield LA, Wouters EF, Saris WH (1997) Plasma concentration of total leptin and human lung-cancer-associated cachexia. Clin Sci 93:273–277PubMedGoogle Scholar
  20. 20.
    Acharyya S, Ladner KJ, Nelsen LL, Damrauer J, Reiser PJ, Swoap S, Guttridge DC (2004) Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J Clin Invest 114:370–378PubMedGoogle Scholar
  21. 21.
    Wang B, Jenkins JR, Trayhurn P (2005) Expression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture: integrated response to TNF-alpha. Am J Physiol Endocrinol Metab 288:731–740CrossRefGoogle Scholar
  22. 22.
    Weryńska B, Kosacka M, Gołecki M, Jankowska R (2009) Leptin serum levels in cachectic and non-cachectic lung cancer patients. Pneumonol Alergol Pol 77:500–506PubMedGoogle Scholar
  23. 23.
    Jamieson NB, Brown JFD, Wallace AM, McMillan DC (2004) Adiponectin and the systemic inflammatory response in weight-losing patients with non-small cell lung cancer. Cytokine 27:90–92PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Sule T. Gulen
    • 1
  • Fisun Karadag
    • 1
    Email author
  • Aslihan B. Karul
    • 2
  • Naciye Kilicarslan
    • 2
  • Emel Ceylan
    • 1
  • Nilgun K. Kuman
    • 3
  • Orhan Cildag
    • 1
  1. 1.Department of Chest Diseases, School of MedicineAdnan Menderes UniversityAydinTurkey
  2. 2.Department of Biochemistry, School of MedicineAdnan Menderes UniversityAydinTurkey
  3. 3.Department of Thoracic Surgery, School of MedicineAdnan Menderes UniversityAydinTurkey

Personalised recommendations